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Letters to Editor
An outline of the lesion was drawn on transparent plastic
to evaluate the results; an estimation of the area of the ulcer was
achieved by measuring the largest cephalocaudal (CC) and
mediolateral (ML) lengths. The initial area of 1.5 cm2 was reduced
by 80% to 0.3 cm2 with treatment: 60% in length and 50% in
width (Figures 1 & 2).
Hydroxyurea improves the antioxidant defense of patients
with sickle cell anemia and contributes to a higher catalase activity
and trolox-equivalent antioxidant capacity levels and lower lipid
peroxidation.(4) However this patient was not taking hydroxyurea
and thus lipid peroxidation may be the cause of the recurring leg
ulcers.
This easily applied therapy was effective and fast in the
management of the ulcer and improved the quality of life of the
patient.
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Figure 2 – Evolution of the ulcer: at the beginning (A), during treatment
with low-power laser therapy (B and C) and after treatment (D)
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Recent immunophenotypic studies
demonstrated that the expression of aberrant
antigens in myeloma plasma cells (MPCs) is a
common feature. The most frequent aberrant
antigens in MPCs are: CD56 (75%) and
CD117 (63%). Several reports suggest that
multiple myeloma (MM) patients with CD56
negative MPCs present with aggressive disease
and have a worse outcome.(1-3) Van Camp et al.
were the first to demonstrate that in the context
of high-dose chemotherapy and autologous
stem cell transplantation, CD56 negative cases
behaved similarly to CD56 positive cases.(4)
These results are encouraging, but we would
like to mention that other immunophenotypic
and genetic characteristics have also
demonstrated clinical impact. In particular, the
rare phenotype, CD19+CD56-, which is
generally found in normal plasma cells,(3)
Multiples aberrant phenotypes in multiple myeloma patient expressing CD56-,
CD28+,CD19+
Luiz Arthur Calheiros Leite1,2
Daniela Márcia Bahia Kerbauy1
Elisa Kimura1
Mihoko Yamamoto1
1
Universidade Federal de São Paulo – UNIFESP,
São Paulo, SP, Brazil
2
Universidade Federal de Pernambuco – UFPE,
Recife, PE, Brazil
Conflict-of-interest disclosure: The authors
declare no competing financial interest
Submitted: 11/5/2011
Accepted: 12/4/2011
Corresponding author:
Luiz Arthur Calheiros Leite
Universidade Federal de São Paulo – UNIFESP
Rua Pedro de Toledo, 650, 3º andar
04023-900 – São Paulo, SP, Brazil
Phone: 55 11 5579-1550
lahemato@hotmail.com
DOI: 10.5581/1516-8484.20120019
responds poorly to combination chemotherapy.
Here, we describe a case in which plasma
cells expressed the CD19+CD56- phenotype
as well as several other aberrant antigens
(CD20+, CD22+, CD28+, CD33+, CD117+,
HLA-DR+).
A 60-year-old man was admitted with
back pain and weight loss over a 4-month
period. Laboratory tests showed: red blood
cell count: 2.8 x 1012/L; hemoglobin: 7.5 g/dL;
platelet count: 161 x 109/L; and leukocyte count
3.5 x 109/L. The creatinine level was normal,
but serum ionic calcium was 1.30 mg/dL.
The serum total protein concentration was
15.8g/dL and albumin 2.06 g/dL. Serum ß2-
microglobulin was 7.2 mg/L, and monoclonal
component was 7.69 in gamma globulin. IgG
was 9160 mg/dL, IgA was 12 mg/dL and IgM
< 4 mg/dL. Bence Jones kappa protein was
Figure 1 – Outline of the leg ulcer on clear plastic before treatment
(left) and after laser therapy (right)
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found in urine. A bone marrow (BM) biopsy revealed a
hypercellular marrow with 95% of dysplastic plasma cells.
There were extensive osteolytic bone lesions in the thoracic
spine and bone fractures in L5. A diagnosis of multiple myeloma
(IgG kappa, stage IIIA) was made.
Four-color flow cytometry of fresh BM cells revealed that
the myeloma cells expressed CD38, CD138, CD19, CD20, CD22,
CD33, CD28, CD117, HLA-DR but no CD56 or CD45 (Figure
1). The cells were positive for cytoplasmic immunoglobulin
kappa light chain. Cytogenetic studies revealed a hyperdiploid
karyotype and no rearrangement of the IgH gene or deletion of
13q14. The patient was treated with one cycle of the VAD
(vincristine 0.4 mg/day, doxorrubicine 9 mg/day and
dexamethasone 40 mg days 1-4, 9-12, and 17-21) regimen, and
two cycles of the VMMD (vincristine 1.5 mg/day i.v, day 1;
ranimustine 50 mg/day, day 1; dexamethasone 40 mg days 1-4,
9-12, and 17-21 and melphalan 8 mg p.o, days 1-6) and MP
(melphalan 10 mg and prednisolone 50 mg p.o days 1-4) regimes,
without any significant improvement. The patient died due to
systemic infection.
cases should receive intensive treatment that can overcome the
poor response(3). However, it would be interesting to evaluate
the cases reported by them in the context of other prognostic
features: according to other aberrant antigens, such as CD28+,
and myeloid associated antigens. Interestingly, they did not find
any association of CD56 negative cases with genetic risk groups,
including deletion 13q, p53 gene mutation and IgH translocations.
Our case presents the rare CD19+CD56- phenotype with
several other aberrant antigens (CD20+, CD22+, CD28+, CD33+,
CD117+, HLA-DR+). The CD28 antigen is not expressed on
normal B cells or plasma cells and according to Shapiro et al., its
presence is related to advanced disease. Conversely, this patient
presented a hyperdiploid karyotype but no other genetic
alteration with a defined prognosis group as reported by Kyle
and would therefore be classified in a good prognosis group.(2,6)
Mateo et al. reported that non-hyperdiploid MM cases are
associated with positivity for CD28 and CD20 and negative for
CD117, in contrast to the case presented here. These findings
highlight the need of a more comprehensive evaluation that should
include DNA ploidy status, IgH gene rearrangements, del 13q
and del 17p.(7) However, the CD56 expression pattern could be
used as a rapid prognostic risk factor to direct treatment and
predict disease outcome.
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Figure 1– Four-color flow cytometry of fresh bone marrow cells
showing myeloma cells expressing CD38, CD138, CD19, CD20, CD22,
CD33, CD28, CD117, HLA-DR but no CD56 or CD45
Sahara et al. were the first to describe a MM case with the
CD19+CD56- phenotype that was refractory to combination
chemotherapy. They also reported that the lack of CD56 was
related to aggressive disease and significantly shorter survival
than CD56+ cases(5). According to Lin et al., these CD56 negative
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